Results 161 to 170 of about 3,069,601 (247)

LAMC2+ Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3/STAT3/CD44 Axis

Cancer Science, EarlyView.
This study identified LAMC2+ epithelial cells through single‐cell sequencing and found that high expression of LAMC2 is associated with the malignant progression of bladder cancer. HdWGCNA and transcriptome sequencing revealed the SerpinB3/STAT3/CD44 axis. Diosmetin was selected as a potential LAMC2 inhibitor.
Yutong Chen, Yunzhong Jiang, Zezhong Yang, Minxuan Jing, Wentai Wu, Jiale He, Lu Wang, Minghai Ma, Yaodong Zhang, Min Wang, Jianpeng Li, Yuanchun Pu, Bingliang He, Yanjia Liu, Kaibo Mi, Hang Liu, Mengzhao Zhang, Jinhai Fan   +17 more
wiley   +1 more source

Cancer Trends: Primary Liver Cancer

, 2016
During 2012-2014, a little over half (58%) of all primary liver cancers were histologically confirmed, 37% were diagnosed radiologically only via x-ray, MRI/CT scan etc. and 5% did not have a method of diagnosis specified.
National Cancer Registry Ireland (NCRI)
core  

TRIM59 Drives Bladder Cancer Progression Through E3 Ligase‐Dependent K48‐Linked Degradation of PTRF

Cancer Science, EarlyView.
Schematic model of TRIM59‐driven BLCA progression through K48‐linked ubiquitination and proteasomal degradation of PTRF, leading to AKT activation and c‐Myc upregulation. ABSTRACT Tripartite motif‐containing 59 (TRIM59) is an E3 ubiquitin ligase implicated in multiple malignancies, but its role in bladder cancer (BLCA) remains incompletely understood ...
Junlin Gan, Xuesong Bai, Aijie Zhang, Fei Lin, Hang Tong, Tinghao Li, Ning Xu, Xinyuan Li, Zhou Yu, Hubin Yin   +9 more
wiley   +1 more source

SLAMF6 Enhances the Efficacy of Anti‐PD‐L1 Immunotherapy in CRC Through the STAT1/CXCL10 Signaling Axis

Cancer Science, EarlyView.
SLAMF6 recruits SHP‐2 to activate STAT1, upregulates CXCL10 and PD‐L1, promotes CD8+T cell infiltration, and enhances the efficacy of anti‐PD‐L1 therapy. ABSTRACT As a T‐cell receptor co‐stimulatory protein, signaling lymphocyte activation molecule family 6 (SLAMF6) is a member of the immune cell activating receptor family and is expressed on T cells ...
Yu Wu, Xinhui Lv, Shunhao Zhang, Yafang Chen, Sicong Liu, Feiyang Song, Chunmei Zhao, Guihua Wang, Xudong Wang   +8 more
wiley   +1 more source

Additivity, Not Synergy, Underlies the Efficacy of Current Combination Regimens in Urothelial Cancer. [PDF]

Cancer Res Commun
Schlachter NM, Miller EJ, Anker JF, Galsky MD, Palmer AC.   +4 more
europepmc   +1 more source

Integrated Analysis of HER2 Expression and ERBB2 Alterations in Bladder Cancer

Cancer Science, EarlyView.
Integrated analysis of 445 bladder cancers showed that HER2 membrane expression and ERBB2 amplification are distinct features. HER2 expression overlapped with NECTIN4 expression, whereas ERBB2 amplification was enriched in the LumU subtype and associated with poor prognosis.
Kensuke Hirosuna, Kazuki Nishimura, Moritoshi Sakamoto, Satoshi Tokushige, Keita Nakamori, Tomohisa Matsunaga, Yuki Yoshikawa, Takeshi Tsutsumi, Ryoichi Maenosono, Takuya Tsujino, Masahiko Ajiro, Haruhito Azuma, Akihide Yoshimi, Kazumasa Komura   +13 more
wiley   +1 more source

Pancreatic Metastases from Urothelial Cancer. [PDF]

Eur J Case Rep Intern Med
Kyrkasiadou M, Papanikolaou IS, Politi E, Nikolaidou V, Kakogianni K, Mara K, Bamias A.   +6 more
europepmc   +1 more source

Liquid Biopsy and Multi‐Cancer Early Detection Tests for Cancer Screening: A Scoping Review

Clinical Genetics, EarlyView.
There is a large body of evidence on liquid biopsy and multi‐cancer detection tests for cancer screening. Most studies addressed test performance outcomes, while fewer addressed clinical outcomes, implementation, and cost‐effectiveness. No studies evaluated cancer mortality.
Tessa Robinson, Marian Saab, Lily Thao Nguyen, Pooja Kochar, Olivia Meggetto, Jill Tinmouth, Meghan J. Walker   +6 more
wiley   +1 more source

Toxicity related to immunotherapy in urothelial cancer: Tumour genetic risk variants. [PDF]

Pharmacogenomics J
Rodríguez-Piñas JM, Romero-Lorca A, Novillo A, Gaibar M, Rubio M, Antón-Pascual B, Hernando S, Alemany I, Camacho FI, Cavanagh M, Boiza M, Marrupe D, Martín AM, Khedaoui R, Fernández-Santander A.   +14 more
europepmc   +1 more source

NFE2L2‐mutated urothelial carcinomas frequently show concomitant myxoid and squamous features and have high PD‐L1 expression

Histopathology, EarlyView.
Aims NFE2L2 encodes the transcription factor, NRF2, which is a regulator of cellular oxidative stress responses and metabolic homeostasis. NFE2L2 alterations are implicated in multiple cancers, with significant study in thoracic oncology, with an adverse prognosis, aggressive behaviour, metabolic reprogramming and diminished responses to chemotherapy ...
Dane Wuori, Alexander Guzzetta, Melissa Y. Tjota, Peng Wang, Tatjana Antic, Jung Woo Kwon   +5 more
wiley   +1 more source